Fig 4. NEO212 can radiosensitize TMZ-resistant GB cells at clinically relevant concentrations.

In these CFA analyses, we tested both TMZ and NEO212 drugs using a treatment schedule designed to mimic the Stupp protocol which allows for synergisms to be observed (i.e., five consecutive days of concurrent chemotherapy plus radiotherapy vs. five consecutive days of monotherapies). The colony survival data show that NEO212 can synergize with ionizing radiation in the clinically relevant concentration range (i.e., 10 μM or less), whereas TMZ becomes synergistic only outside (i.e., >10 μM) this concentration range where presumably achieves levels of DNA alkylation that are optimal for synergistic effects to take place (* indicates a p<0.01 determined by Student’s t-test).